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Background: Multiple sclerosis (MS) is a chronic progressive and inflammatory disease of 
the central nervous system that is characterized by demyelination in the central nervous system. 
In regard to the prevalence of diseases and enormous costs imposed on society and the health 
system, finding a way to stop the progression of the disease using drugs with fewer side effects 
seems a serious sanitation issue to the health of the international community. This study aimed 
to evaluate the effect of evening primrose oil (EPO) on fatigue and quality of life in patients 
with MS.
Materials and methods: In this double-blind randomized clinical trial, 52 patients with MS 
were chosen and categorized into 2 groups which received 2 doses of EPO and placebo. In addi-
tion, the quality of life and fatigue scale in these patients were investigated before the treatment 
and again 3 months after therapy. The findings were then compared between the 2 groups.
Result: EPO consumption significantly increased cognitive function, vitality, and overall life 
satisfaction and also reduced pain and fatigue compared to placebo (P,0.05).
Conclusion: Our findings indicated that EPO consumption had no impact on the quality of 
life in general; however, it had a significant effect on several important aspects of life quality 
such as the increase of cognitive function, vitality, and overall life satisfaction. It also reduced 
the pain and fatigue in comparison to the placebo consumption. Herbal medicines are brittle 
and have fewer side effects than chemical drugs. With use of this plant, reduced fatigue and 
improved quality of life were observed in MS patients. But the drug did not prevent the pro-
gression of the disease.
Keywords: cognitive function, vitality, overall life satisfaction, pain, fatigue
Introduction
Multiple sclerosis (MS) is a chronic progressive inflammatory disease of the central 
nervous system (CNS) that is characterized by demyelination in the CNS and leads 
to inability of individuals (one of the most important pathological features of MS 
is demyelination. The pathology of axonal can be raised but in general pathology 
demyelination is more relevant.1,2 Two to three million people are affected by MS 
worldwide, and every week about 200 new people begin suffering from MS. Eighty 
percent of people with this disorder have some degree of disability.3 The prevalence 
of MS in various geographical areas is different. This disease is widespread in Europe, 
Canada, America, New Zealand, and South Australia and is less commonly seen in 
Asia.4–6 In recent years, studies in the Middle East and Iran indicate a high preva-
lence of the disease in these regions.3 In Iran, the prevalence of this disease has been 
reported 30–40 per 100,000 persons (Iran was previously only a low-prevalence area 
for MS, but recently, with increasing prevalence of Iran, it has been classified as an 
intermediate region).3 In most countries, economic concerns due to this disease are 
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more significant than stroke and Alzheimer because MS is 
more common in young individuals and also because this 
is a chronic and long-term illness, per se. The annual costs 
in America have been estimated at $5.2 million.3
The cause of the disease is still not fully recognized, and 
various theories are presented in this regard. Items such as 
heredity, environmental factors, and even viruses can be 
introduced as the underlying causes of the disease.7–9 There 
is much evidence that it is an autoimmune disease.
Studies have shown that in these patients inflammatory 
factor levels (CRP) are increased and these factors have 
myelotoxic property directly and cause demyelination and 
axonal damage.7
Among the environmental factors, nutritional factors are 
recognized as one of the most important of possible reasons 
in MS outbreak. Although available epidemiological studies 
have provided conflicting evidence, these investigations 
point to the role of some factors in control and prevention of 
MS disease such as vitamin D, polyunsaturated fatty acids, 
particularly omega-3 and omega-6, antioxidants such as 
vitamin C, dietary fiber, vegetative protein, fish, juice, and 
whole grains; however, other factors such as saturated and 
animal fat, red meat, and high-fat dairy are the known risk 
factors in this disease.4,10,11
In regard to the increasing rate of mortality, issues such 
as enormous costs, various problems of MS patients, taking 
care of these patients, and attempts to decrease the difficulties 
and symptoms of MS disease are all essential.
Today, medicinal plants are economically important 
and are used raw or processed in modern and traditional 
medicine.12 The use of herbal products is increasing 
worldwide, and the World Health Organization studies 
indicate that 80% of the world population is dependent on 
plants in terms of medical aspects.13
Evening primrose, with the scientific name of Oenothera 
biennis, belongs to the family of panacea plants.14 Evening 
primrose as a medicinal plant has a long history and has a 
high potential in terms of producing gamma-linolenic acid 
(GLA). Mature and dried seeds constitute medicinal aspect of 
this plant, containing the effective oil substance.15 This plant 
oil contains an essential fatty acid called GLA acid which is 
an important intermediate in the human body metabolism. 
Evening primrose oil (EPO) consists of 98% triacylglycerol, 
and about 1%–2% of nonsoap material and some important 
sterols and tocopherols. The major fatty acids in EPO are 
palmitic acid (7%–10%), stearic acid (1/5%–3/5%), oleic 
acid (6%–11%), linoleic acid (65%–80%), and γ-linolenic 
acid (8%–14%).16,17 The findings of previous studies revealed 
that linoleic acid and γ-linolenic acid are able to prevent 
prostaglandins synthesis.14
The main origin of this plant is South America and 
Central America. The brewed root of this plant is used in 
these regions against obesity and intestinal pain. Evening 
primrose seed oil is very effective in reducing menstrual 
pain and in the treatment of diabetes mellitus and for reduc-
ing cholesterol. Useful therapeutic effects of this plant are 
also significantly observed with regard to the symptoms 
of irritable bowel, and for blood circulation disorders and 
rheumatism.18
In regard to the prevalence of the disease and enormous 
costs imposed on society and the health system, finding a way 
to stop the progression of the disease using drugs with fewer 
side effects seems a serious issue in the health of international 
community. Therefore, this study aims to evaluate the effect 
of EPO on fatigue and quality of life in patients suffering from 
MS. Our goal was to prevent the progression of symptoms 
and to improve some of the symptoms, but preventing the 
transformation of relapsing/remitting MS to progressive was 
not a goal of the study.
The purpose of this study was to evaluate the effect of 
EPO on fatigue and quality of life, but a comparison of the 
effect of this oil on these 2 factors (fatigue and quality of 
life) was not a goal of the study.
The following subscales were used:
1. Physical health: This scale evaluates the individual in 
terms of physical condition and was evaluated using 
12 questions in the Multiple Sclerosis Quality of Life 
(MSQL-54) questionnaire.
2. Role playing in relation to physical status: This scale eval-
uates the limitations that follow for a person’s physical 
condition, assessed by 4 questions in the questionnaire.
3. Role in relation to psychological state: This scale evalu-
ates the limitations that follow a person’s mental status, 
assessed by 4 questions in the questionnaire.
4. Pain: This scale evaluates the generalized pain caused 
by MS in patients, which was evaluated by 3 questions 
in the questionnaire.
5. Vitality: This scale evaluates happiness the person’s feels 
and was evaluated by 4 questions in the questionnaire.
6. Energy: This scale assesses the individual’s energy and 
energy for doing routines and extra tasks, which was 
evaluated by 6 questions in the questionnaire.
7. Understanding general health: This scale assesses whether 
a person understands his own health and whether a person 
knows what health is, and was evaluated by 4 questions 
in the questionnaire.
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 8. Social function: This scale assesses the social constraints 
imposed upon by the disease on the individual, and was 
evaluated by 6 questions in the questionnaire.
 9. Cognitive function: This scale assesses how the disease 
MS affects the memory and concentration of the person. 
It was assessed by 4 questions in the questionnaire.
10. Health threat: This scale examines how much the 
disease can threaten a person’s health. It was assessed 
by 4 questions in the questionnaire.
 11. Sexual function: This scale measures the ability of a 
person’s sexual function to determine how much the 
disease can affect sexual function of the individual, which 
was evaluated by 5 questions in the questionnaire.
 12. Total individual satisfaction of life: This scale deter-
mines how much this disease can affect the overall 
satisfaction of one’s life. It was assessed by 2 questions 
in the questionnaire.
Literature review
New research showed that non-triglyceride fraction of unre-
fined EPO to contain triple-oxidated trans-caffeoy derivatives 
of betulinic, morolic, and oleanolic acid. These lipophilic 
pentacyclic triterpenes have free radical scavenging, cycloox-
ygenase and neutrophil elastase inhibitory activities. Thus, 
this may be useful for human health. Nevertheless, labora-
tory analysis has shown that these lipophilic antioxidants are 
seen only in trace quantities in EPO commercial samples. 
Due to useful effect of triterpene esters, scientists postulate 
that this product is likely to have better health benefits than 
conventional EPO preparations.21
The result of new studies demonstrated that myalgic 
encephalomyelitis has a relationship with viral infection. 
Also, it must be pointed out that such infections, by inhibiting 
the delta-6 desaturation (D6D) of the precursor essential fatty 
acids including linoleic acid and α-linolenic acid, impair the 
ability of the person to biosynthesize long-chain polyunsatu-
rated fatty acids, thereby leading to an adverse effect on the 
biosynthesis of eicosanoids from the chain polyunsaturated 
fatty acids dihomo-γ-linolenic acid, arachidonic acid, and 
eicosapentaenoic acid, which fits in well with the symptoms 
and signs of myalgic envephalomyelitis. So, virgin cold-
pressed non-raffinated EPO was suggested for treatment in 
patients with the disease.22
In one study, 90 patients with Sjogren’s syndrome entered 
a 6-month study for treatment with EPO. By assessing 
using the Visual Analog Scale, it was found that no sta-
tistically significant improvement was observed in fatigue 
during a 24-hour period between the 2 groups. Finally, the 
authors suggested that EPO for fatigue in primary Sjogren’s 
syndrome is ineffective.23
In post-viral fatigue syndrome patients, the researchers 
studied the effect of essential fatty acid therapy. The prepara-
tion that they used contained linoleic acid, eicosapentaenoic 
acid, and docosahexaenoic acid, and the patients received 
either the preparation or a placebo. There were no adverse 
events reported. They suggested that essential fatty acids 
provide an effective, rational, and safe treatment for this 
syndrome.24
EPO is taken orally in the form of a gel capsule and has 
been used for breast pain and atopic dermatitis treatment.27,28 
EPO is necessary for many functions, but there is not enough 
evidence to prescribe its use for the relief of atopic dermatitis 
or breast pain.25
Materials and methods
Due to the high prevalence of fatigue in MS patients, most of 
our patients were also tired of the Modified Fatigue Impact 
Scale (MFIS). Apart from depression, other secondary causes 
of fatigue included endocrine abnormalities; liver, heart, and 
pulmonary conditions, and autoimmune diseases, and people 
whose fatigue caused them the abovementioned symptoms 
were excluded.
Before the implementation of the plan, capsules contain-
ing 1 g of EPO as well as placebo capsules were provided in 
a predetermined number.
Method of preparation of the capsule: The soft gelatin 
capsule of the evening primrose and placebo was placed on 
the market by Barije Pharmaceutical Company, Kashan, 
Iran.
Gloricum oil was standardized on the basis of its GLA 
content using standard chromatography gas apparatus, (GC 
Clarus 680 Chromatography Machine, made by Perkin 
Elmer, Waltham, MA, USA). The characteristics of the 
column were as follows:
1. Fixed phase Wcot Fused Silica Type CP-Column 7753 
(CP-WAX 52 CB).
2. Dimensions of the pillar: column length: 50 m, inner 
diameter: 0.32 mm, outer diameter: 0.45 mm, and film 
thickness: 0.20 µm.
3. For chromatography, the moving phase had a con-
stant speed of 1 mL/min, injector output was 250°C, 
the temperature of the detector was 250°C, injection 
rate was 1 µL, spilite was 50, and the temperature 
program used was as follows: starting at 170°C with 
increase of 3°C/min, 20 minutes at 230°C, for total time 
40 minutes.
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Then soft gelatin capsule with gelatin shell coating was 
made by softgel coating. After drying, it was poured into 
the flacon, and following quality control checks was given 
to the project executives.
In this double-blind randomized clinical trial (both the 
patient and the donor are unaware of the type of medication 
[placebo or EPO], and the sampling method used was a ran-
domized one with 4-way permutation sequences [a statistical 
method for sampling]), 52 MS patients whose disease was 
approved through standard diagnostic procedures were studied. 
These patients were chosen among the people who were admit-
ted to Golestan Hospital, a part of the MS society of Ahwaz.
Diagnosis of the disease was based on neurological 
examinations and MRI by a neurologist.
Included patients were referred from a neurology specialist’s 
office and should have fulfilled the following criteria:
1. Diagnosis of the disease based on neurological examina-
tions and MRI by a neurologist.
2. 18–55 years old.
3. Expanded Disability Status Scale (EDSS) score ,6.
4. No other neurological disease, such as stroke or psychi-
atric condition, such as depression.
5. Women who were not pregnant.
6. Absence of diseases such as cancer, autoimmune diseases 
such as lupus or rheumatoid arthritis, and heart disease.
7. Not having suffered a new attack in the past month and 
had not use pulse corticosteroids.
The parameters that were influenced by the EPO are really 
different, which is significant.
Ahwaz Jundishapur University’s ethics committee 
approved this research, and all patients were deliberately 
enrolled. Before entering the study, written informed consent 
was obtained from all patients.
The biographical information of these patients was 
recorded, and they were asked to complete a question-
naire regarding life quality of Iranians with MS disease. 
The questionnaires used were Multiple Sclerosis Quality Of 
Life (MSQOL)-54 and MFIS. The use of multiple different 
pain scales was avoided. Based on the MFIS questionnaire, 
we compared fatigue into two groups (experimental and 
control) but did not compare the fatigue of components 
separately (physical, cognitive and psychosocial) in the 
two groups.
Patients were randomly divided into 2 groups.
The experimental group: Patients were asked to take 1 g 
oral capsule containing EPO every 12 hours for 3 months in 
addition to the standard treatment for their disease.
 Control group: Patients were administered the standard 
medicinal therapy for disease along with placebo.
After 3 months, all the patients were asked to return to 
the medical center and retake the MSQOL-54 and MFIS 
questionnaires.
The results of these questionnaires were statistically 
analyzed.
Table 1 shows the patient’s clinical and demographic 
characteristics.
statistical analysis
After the results were obtained through tests and question-
naires, the required data were statistically analyzed using 
SPSS, version 22 (IBM Corporation, Armonk, NY, USA). 
Descriptive statistics were also utilized in order to analyze 
the dataset.
Covariance analysis was then employed, since in addition 
to the independent variable (2 groups of drug and placebo) 
and the dependent variable (quality of life and fatigue in 
Table 1 Patient’s clinical and demographic characteristics
Study group Control group Experimental group
Number 26 patients 26 patients
gender Female Male Female Male
18 8 20 6
age 20–55 years old 20–55 years old
Disease duration 1–5 years 1–5 years
Ms type rrMs rrMs
Disease modifying treatment interferon β 1a (cinovex) or glatiramer interferon β 1a (cinovex) or glatiramer
eDss ,6 and more patients were 1–3 ,6 and more patients were 1–3
Depression score 0–7 normal 0–7 normal
Note: Depression scores in patients ranging from 0 to 7 were considered in the normal range and were included in the study, but those with a depression score over 7 
were considered depressed and were not included in the study from the beginning.
Abbreviations: rrMs, relapsing/remitting multiple sclerosis; eDss, expanded Disability status scale; Ms, multiple sclerosis.
Neuropsychiatric Disease and Treatment 2018:14 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1509
The effect of ePO on fatigue and quality of life in patients with Ms
patients 3 months after treatment), there was a third variable 
called covariate (pretest) (fatigue and quality of life in 
patients before treatment) in this study.
The basic assumptions for all covariance tests were the 
normality, homogeneity of variance, and homogeneity of 
regression slope.
Kolmogorov–Smirnov test was used for checking the 
normality, and Levene’s test was employed in order to evalu-
ate the homogeneity of variance.
The significant level was P,0.05.
The results obtained from the assumptions of normal-
ity and homogeneity of variances indicated no significant 
deviation. In order to examine the differences between quality 
of life and fatigue variables between the experimental and 
control groups, analysis of covariance was employed.
The dependent variables were the quality of life and 
fatigue in patients 3 months after treatment, and control 
variables or covariates were the quality of life and fatigue 
in patients before treatment.
The basic assumptions, normality, and homogeneity of 
variances, were evaluated. No significant interaction between 
covariate and independent variables was seen, which reveals 
that there was no interaction between these 2 variables. 
Therefore, the assumption of homogeneity regression line 
slopes was met.
Results
The findings obtained from the covariance analysis showed 
that there was a significant difference between the average 
of vitality scale, pain scale, overall satisfaction with life, 
cognitive function, and fatigue in the experimental group 
compared with the control group 3 months after the initia-
tion of treatment.
According to the results, at the significance level of 
0.05, there was a significant difference between the average 
of vitality scale after 3 months of treatment in both groups, 
control (placebo) and experimental, P=0.024. This meant 
that the independent variable (group) had a significant effect 
(Figure 1).
With reference to the results at the significant level of 
0.05, there was a significant difference between the average 
results seen on the pain scale after 3 months of treatment in 
both groups, control (placebo) and experimental, P,0.001. 
In other words, the effect of the independent variable (group) 
was significant (Figure 2).
According to the results at the significant level of 0.05, 
there was a significant difference between the average 
scores on the cognitive functioning scale after 3 months of 
treatment in both control (placebo) and experimental groups, 
P,0.001. In other words, the independent variable (group) 
had a significant effect (Figure 3).
With reference to the results at the significant level of 
0.05, there was a significant difference between the aver-
age score of overall satisfaction with life after 3 months of 
treatment in both control (placebo) and experimental groups, 
P,0.001. In other words, the effect of the independent vari-
able (group) was significant (Figure 4).
According to the results at the significant level of 0.05, 
there was a significant difference between the average scores 
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after treatment in the 2 groups, control (placebo) and experimental.
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on the fatigue scale after 3 months of treatment in both con-
trol (placebo) and experimental groups, P,0.001. In other 
words, the independent variable (group) had a significant 
effect (Figure 5).
However, there was no significant difference between the 
average scores of physical health, role in relation to health, 
playing a role in mental status, social functioning, energy, 
sexual function, health perception, and health hazards in 
the experimental group compared with the control group 
3 months after the treatment (P.0.05).
The results also indicated there was a significant effect 
of the control (covariate) variable (P,0.05).
Overall results
It can be claimed that after removing the effect of the con-
trol variable (covariate), a significant different was found 
between the average scores of vitality, pain, overall life 
satisfaction, cognitive function, and fatigue after 3 months of 
treatment in both control (placebo) and experimental groups 
(EPO consumers).
Therefore, the use of EPO after 3 months in the experi-
mental group led to an increase in vitality, overall satisfaction 
with life, and cognitive function and a reduction in scores on 
the pain scale and fatigue scale significantly.
The comparison of pain scale, vitality, overall life satis-
faction, cognitive function, and fatigue before treatment 
and 3 months after treatment in the 2 groups, control and 
experimental, is illustrated in Figures 1–5.
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The study we performed was unique, and there is no 
similar study available for comparison of the results with, 
and there were only 5 relatively similar studies that we found 
upon literature review.
Discussion
The cause of MS is still not fully recognized, and vari-
ous theories are presented in this regard. There is much 
evidence that it is an autoimmune disease.
The findings obtained through this study revealed that the 
EPO consumption in MS disease had no impact on quality 
of life in general; however, there was a significant effect 
on 4 important aspects of quality of life in comparison to 
the consumption to patients who consumed the placebo: 
increase of cognitive function, vitality, overall satisfaction 
with life, and decrease in pain. Moreover, the use of EPO 
in comparison with placebo consumption had a significant 
effect on reduction of fatigue scale scores (P,0.05).
Rezapour-Firouzi et al19 examined the efficacy of a com-
bination drug containing hemp and evening primrose in order 
to reduce EDSS and the level of liver enzymes in 23 patients 
with MS and showed that this drug has beneficial effects in 
improving the clinical symptoms.
Parameters influenced by EPO are really different, which 
is noteworthy. In our study, we declared that the parameters 
of pain, vitality, fatigue, cognitive impairment, and quality of 
life in general were modified by EPO. It has been shown that 
Rezapour-Firouzi et al20 worked on EPO and cannabis and 
concluded that EPO and cannabis have beneficial effects on the 
improvement of EDSS score and the activity of liver enzymes 
in MS patients. Alvandipour et al26 studied EPO and Vitamin E, 
and they came to the conclusion that vitamin E and EPO have 
similar therapeutic effects in treating periodic breast pains and 
that it can be used as therapeutic alternatives in this area.
Conclusion
To the best of our knowledge, this study is unique in terms 
of the examination of the effect of EPO on life quality and 
fatigue in patients with MS and the novel use of question-
naire. During the study, we stated several times that we used 
questionnaires to investigate the effect of EPO on fatigue 
and quality of life of MS patients. We could not use other 
scales because of the controversy with the title of the paper. 
The values in the placebo group were identical before and 
after treatment and we did not have any interactions in the 
numbers, and indeed the values were close or identical.
Considering the findings obtained in this study that EPO 
has a significant effect on 4 aspects of quality of life and fatigue 
in comparison to the placebo, using a larger drug dosage and 
increasing the duration of the study (more than 3 months) are 
recommended for future studies. Besides, the lack of long-
term follow-up of patients was the limitation of this study.
In addition to the above limitation, our study also did not 
take into consideration MS patients younger than 18 years 
of age.
Approximately 80%–97% of patients with MS complain 
of fatigue, and while the real cause of disease is unknown, 
nonpharmacological treatments for reducing fatigue include 
taking cold drinks, aerobic exercise, and resting. Many clini-
cal studies examine the effect of fatigue control with the use 
of CNS modifiers such as methylphenidate, modafinil, and 
pumilein, and results have been proven. In addition, factors 
such as buprupion, sertraline, amantadene, and aminopyri-
dine have also been shown to reduce fatigue due to MS.
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